ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.59 USD
-0.15 (-0.90%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $16.57 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ACAD 16.59 -0.15(-0.90%)
Will ACAD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACAD
Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
Other News for ACAD
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals announces Health Canada acceptance of trofinetide NDS
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting